Brief: Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating Ov329 Does Not Accumulate In Animal Eyes In Contrast With Vigabatrin

Ovid Therapeutics

26/09/2024 13:16

Sept 26 (Reuters) - Ovid Therapeutics Inc  OVID.O :
    * OVID THERAPEUTICS PRESENTS PRE-CLINICAL STUDY RESULTS
DEMONSTRATING OV329 DOES NOT ACCUMULATE IN ANIMAL EYES IN
CONTRAST WITH VIGABATRIN
    * OVID THERAPEUTICS INC: STUDY FOUND OV329 CLEARED AND
REMAINED
UNDETECTABLE IN RETINA, EYE, AND BRAIN TISSUES OF MICE
    * OVID THERAPEUTICS INC: PHASE 1 TRIAL EVALUATING OV329 IN
HEALTHY
VOLUNTEERS IS ON-TRACK FOR COMPLETION IN LATE 2024

Source text for Eikon:  ID:nGNX2R71ZT 
Further company coverage:  OVID.O 

 ((Reuters.Briefs@thomsonreuters.com;))